Moreover, preclinical data have convincingly supported the therapeutic potential CRH receptor antagonists/agonists, although the specific patient profile that may benefit from such pharmacological treatment remains to be identified, as is the case for the role of CRH in the neurobiology of depression. This evidence concerns the gene CRH and depressive symptom measurement.